Histology News and Research

RSS

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Multi-modality imaging to identify plaque

Late-breaking results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

25 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Biovista's BVA-201 drug for MS shows positive results

Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

10 Sep 2009

New method found for the diagnosis of cartilage disease

In its quest to find new strategies to treat osteoarthritis and other diseases, a Boston University-led research team has reported finding a new computer tomography contrast agent for visualizing the special distributions of glycosaminoglycans (GAGs) - the anionic sugars that account for the strength of joint cartilage.

2 Sep 2009

Granulation tissue formed under gauze-based NPWT produces less scarring

At the 5th Joint Meeting of the European Tissue Repair Society and The Wound Healing Society in Limoges, France, Associate Professor Malin Malmsjo, MD, PhD of Lund University in Sweden presented never before seen ground-breaking research revealing that granulation tissue formed under gauze-based Negative Pressure Wound Therapy (NPWT) is more organized and contains fewer leukocytes than the granulation tissue formed under foam.

1 Sep 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

Nonsurgical, quick and accurate test for diagnosing endometriosis discovered

A quick and accurate test for endometriosis that does not require surgery has been developed by researchers from Australia, Jordan and Belgium, according to new research published online today (Wednesday 19 August) in Europe's leading reproductive medicine journal Human Reproduction.

19 Aug 2009

UT Southwestern Medical Center grant aids study of lung cancer in people who never smoked

Researchers at UT Southwestern Medical Center are among an elite group of cancer scientists to share a $2 million grant to find biomarkers for lung cancer that develops in people who have never smoked.

21 Jul 2009

Sunitinib shows promise for advanced kidney cancer patients with poor prognosis

Sunitinib prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer (metastatic renal cell carcinoma) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain, finds an Article published Online First (www.thelancet.com) and in the August edition of The Lancet Oncology.

16 Jul 2009

FDA approves Alimta (pemetrexed) for advanced lung cancer

The U.S. Food and Drug Administration has approved Alimta (pemetrexed), the first drug available for maintenance therapy of advanced or metastatic lung cancer.

6 Jul 2009

Experimental imaging technique reveals ‘tell tale’ brain plaques in Alzheimer's

Researchers at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have demonstrated a new, highly detailed x-ray imaging technique that could be developed into a method for early diagnosis of Alzheimer's disease.

15 Jun 2009

New imaging technique: toward spinal cord regeneration?

The axon is a part of the neuron through which nerve impulses are transmitted, and at the end of which is located the synapse, which connects it to another neuron. In the event of a lesion, the axon is the component which must be regenerated in order to restore the connections between the different neurons and re-form the nerve.

5 Jun 2009

Breast elastography allows for a more accurate diagnosis of breast cancer

Breast elastography allows physicians to give a more accurate diagnosis of breast cancer, according to a study performed at Singapore General Hospital in Singapore.

23 Apr 2009

Is telmisartan effective in treating non-alcoholic steatohepatitis?

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

2 Apr 2009

Carnitine supplementation appears to prevent development of liver cancer

A study will be published on March 21, 2009 in World Journal of Gastroenterology addresses the question.

24 Mar 2009

New tumor markers determine therapy intensity

Characteristic changes in the DNA of medulloblastoma, the most frequent malignant brain tumor in childhood, indicate precisely how aggressively the tumor will continue to spread and what the chances of disease relapse are.

17 Mar 2009

Trial looks at telmisartan in treating non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

3 Mar 2009

Study identifies potential 'safe period' for hormone replacement use

A new study makes important new findings on the role of hormone use on the risk of breast cancer, confirming that the use of estrogen plus progesterone increases the risk of both ductal and lobular breast cancer far more than estrogen-only; suggesting a two-year 'safe' period for the use of estrogen and progesterone; and finding that the increased risk for ductal cancers observed in long-term past users of hormone replacement therapy drops off substantially two years after hormone use is stopped.

2 Feb 2009